1.41
0.04 (2.92%)
| Previous Close | 1.37 |
| Open | 1.38 |
| Volume | 1,586,692 |
| Avg. Volume (3M) | 1,491,248 |
| Market Cap | 416,203,776 |
| Price / Earnings (Forward) | 9.14 |
| Price / Sales | 98.92 |
| Price / Book | 7.25 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -1,685.01% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 35.04% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -70.41 M |
| Levered Free Cash Flow (TTM) | -53.20 M |
| Return on Assets (TTM) | -44.04% |
| Return on Equity (TTM) | -278.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Precigen, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.0 |
| Average | -0.88 |
|
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.52% |
| % Held by Institutions | 67.05% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Iridian Asset Management Llc/Ct | 31 Dec 2024 | 5,241,922 |
| Lexaurum Advisors, Llc | 31 Dec 2024 | 691,544 |
| 52 Weeks Range | ||
| Median | 6.00 (325.53%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 12 Jun 2025 | 6.00 (325.53%) | Buy | 1.52 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2025 | Announcement | Precigen Reports First Quarter 2025 Financial Results and Business Updates |
| 16 Apr 2025 | Announcement | Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |